Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 16, 2002BloodOpen Access

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

View Full Paper
Ask AI
Bookmark
Share

Authors

Hagop M. KantarjianHagop M. KantarjianThe University of Texas MD Anderson Cancer CenterJorge E. CortésJorge E. CortésAugusta University HealthSusan O’BrienSusan O’BrienBoston University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kantarjian et al. (2002) studied this question.

synapsesocial.com/papers/6a742654eef1a0b1cf39199bhttps://doi.org/10.1182/blood-2002-02-0545
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase2002 · 295 citations
  2. 2Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation1993 · 375 citations
  3. 3Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study2002 · 1,032 citations
  4. 4Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia2001 · 5,302 citations
  5. 5Long-Term Follow-Up of the Italian Trial of Interferon- Versus Conventional Chemotherapy in Chronic Myeloid Leukemia1998 · 98 citations